Dezamizumab

N/A

Report date: 2022/09/02 20:00:31

Base Information

Drug NameDezamizumab
Drug Alias NameGSK-2398852
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSerum amyloid P-component inhibitors
TargetsSerum amyloid P-component
Therapy Area/IndicationsAmyloidosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPentraxin TherapeuticsGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsAmyloidosis

Other Information

ATC CodeN/A
Related LinksN/A